Retatrutide, an incretin therapy, is primarily studied for its efficacy in weight management and metabolic improvements. Meta-analyses in our corpus indicate significant weight loss, reductions in HbA1c, and improvements in lipid parameters, suggesting a broad impact on cardiometabolic health. It has also shown promise in improving outcomes for kidney transplant patients by reducing new-onset post-transplant diabetes mellitus and offering cardiovascular benefits for individuals with Type 2 Diabetes. Survodutide, also an anti-diabetic agent, is primarily investigated for its potential in treating metabolic dysfunction-associated steatohepatitis (MASH), with evidence suggesting histological efficacy driven by weight loss. While both peptides are associated with weight loss, their primary therapeutic focus within our corpus appears to diverge, with Retatrutide emphasizing broad metabolic and cardiovascular benefits, and Survodutide focusing on MASH treatment.
| Retatrutide | Survodutide | |
|---|---|---|
| Drug class | glp 1 agonist, gip agonist, glucagon agonist | glp 1 agonist, glucagon agonist |
| Studies in corpus | 134 | 37 |
| Highest evidence tier | meta analysis | meta analysis |
| Evidence tier mix | review · 49 preclinical animal · 11 meta analysis · 25 other · 21 rct · 23 in vitro · 1 | rct · 28 meta analysis · 2 review · 3 preclinical animal · 3 |
| Studies with explicit sample size | 2 | 3 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
No direct head-to-head trials in our corpus. Indirect comparison only. Retatrutide's mechanism is described as an incretin therapy, with studies highlighting its role as a GLP-1 receptor agonist. Its efficacy is supported by multiple meta-analyses demonstrating substantial weight loss and significant improvements in glycemic and lipid parameters. Studies also suggest cardiovascular benefits for Type 2 Diabetes and improved metabolic parameters in kidney transplant recipients. However, one meta-analysis notes a lack of diversity in sex, race, and BMI reporting in obesity trials, which could limit the generalizability of findings. Survodutide, also classified as an anti-diabetic agent, is specifically noted for its strong histological efficacy in MASH, with weight loss identified as a primary driver for this improvement. While the corpus mentions a Phase 3 trial for Survodutide detailing participant baselines for obesity treatment, the primary focus of its efficacy studies in our indexed literature is MASH. The corpus does not provide specific dose-response details or side-effect profiles for either peptide.
Looking for vendor-level purity, endotoxin, and HPLC data on Retatrutide or Survodutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.